Program
EP2/EP4/DP1 Antagonist OKN4395
Its studies are mostly in Sarcoma, led by Epkin.
Furthest: phase 1, since Jan 13, 20251 company-led study, 1 open or runningNext primary completion: Jul 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Epkin | 11 open or running | phase 1since Jan 13, 2025 | Jan 13, 2025 | Jul 2028phase 1 · NCT06789172 |
Also a collaborator on its studies: Precision For Medicine.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2025First study: phase 1 study in SarcomaFirst studyNCT06789172 · 146 planned · United States, Australia, United Kingdom
Ahead
- Jul 2028Primary completion: phase 1 study in SarcomaNCT06789172
TargetBeta
PTGER4 →read by rule
“An orally bioavailable, triple antagonist of the human prostaglandin E2 receptor subtypes 2 (EP2) and 4 (EP4), and the prostaglandin D2 receptor (DP1), ”NCIt, by rule
Other programs on PTGER4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| EP4 Receptor Antagonist YY001rule | chongqing-claruvis-pharmaceutical-co-ltd | phase 3 | 6 |
| BMS-986310rule | Ono Pharmaceutical | phase 3 | 6 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06789172Sarcoma · United States, Australia, United Kingdom | 1 | Recruiting | Jul 2028 | 146 |
How it is read
Names in the registry
- “OKN4395”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.